MYC and melanoma: As c-Myc has been demonstrated as a convergent downstream of diverse vemurafenib resistance pathways [49], we believe polyamine biosynthesis and EIF5A hypusination presents generalizable druggable targets that slow recurrence of BRAFi therapy resistant melanoma with diverse genotypes.